# MSD Animal Health

Sequivity RNA particles — Custom RNA replicon vaccines.

Source: https://en.bioecon.ru/companies/msd-animal-health/
Updated: 2026-06-25

- Country: Netherlands

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Revenue | $5.6 billion (2023) | https://www.msd-animal-health.com/downloads/msd-animal-health-corporate-fact-sheet/ |
| Capacity | 55 billion doses per year across all production, with one facility producing 150 million vaccines per day | https://brabantbusinessregion.com/msd-animal-health-opens-new-state-of-the-art-vaccine-factory-in-brabant/, https://investinholland.com/news/msd-animal-health-advanced-vaccine-production-facility-netherlands/, https://msd.nl/boxmeer/ |
| Production site | Boxmeer, Netherlands | https://investinholland.com/news/msd-animal-health-advanced-vaccine-production-facility-netherlands/, https://msd.nl/boxmeer/, https://www.msd-animal-health.nl/wp-content/uploads/sites/14/2020/02/Bedrijfsbrochure_MSD_AH_-_nederlands_-_final_tcm100-186622.pdf |
| Headcount | 800-900 employees at MSD Animal Health Nederland (Boxmeer site reports ~2,000 employees) | https://msd.nl/boxmeer/ |
| Regulatory approval | Sequivity RNA particle platform is licensed by the USDA for multiple swine applications in the US | https://pmc.ncbi.nlm.nih.gov/articles/PMC8528862/, https://www.merck-animal-health-usa.com/newsroom/merck-animal-health-introduces-sequivity-with-microsol-diluvac-forte-adjuvant-prescription-vaccine-for-use-in-gilts-and-sows/, https://www.msd-animal-health.com/about-us/our-story/ |

Independent sources: brabantbusinessregion.com, investinholland.com, merck-animal-health-usa.com, msd.nl, pmc.ncbi.nlm.nih.gov

## Technologies

- [Veterinary biotech & mRNA veterinary drugs](https://en.bioecon.ru/technology/veterinary-biotech-mrna-drugs/)